# InMed Pharmaceuticals Inc. (INM)

Source: https://www.quantisnow.com/company/INM
Generated: 2026-11-18T17:54:13.943Z

- Ticker: INM
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001728328
- Website: inmedpharma.com

## About

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

## Latest INM news and filings

- 2026-11-10 21:45 UTC [SEC Form 8-K] [InMed Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Leadership Update, Financial Statements and Exhibits, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status](https://www.quantisnow.com/insight/inmed-pharmaceuticals-inc-filed-sec-form-8-k-material-modification-to-6784497)
- 2026-11-10 01:18 UTC [Insider Buy] [Large owner Adar1 Capital Management, Llc bought $34,572 worth of shares (2,640 units at $13.10) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-adar1-capital-management-llc-bought-34572-worth-of-6782325)
- 2026-11-09 13:04 UTC [SEC Form 8-K] [InMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inmed-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-6780422)
- 2026-11-06 21:05 UTC [Mergers & Acquisitions] [InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics](https://www.quantisnow.com/insight/inmed-pharmaceuticals-completes-closing-of-merger-with-mentari-therapeutics-6778839)
- 2026-11-05 13:08 UTC [SEC Form 8-K] [InMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inmed-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-6774931)
- 2026-11-05 11:04 UTC [SEC Form 8-K] [InMed Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inmed-pharmaceuticals-inc-filed-sec-form-8-k-amendments-to-articles-6774103)
- 2026-11-03 21:47 UTC [SEC Form 8-K] [InMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inmed-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-6770269)
- 2026-11-03 00:26 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by InMed Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-inmed-pharmaceuticals-inc-6768176)
- 2026-11-02 21:56 UTC [SEC Form 425] [SEC Form 425 filed by InMed Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-inmed-pharmaceuticals-inc-6767726)
- 2026-10-28 21:15 UTC [SEC Form 424B3] [SEC Form 424B3 filed by InMed Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-inmed-pharmaceuticals-inc-6761811)
- 2026-10-27 18:13 UTC [Insider Buy] [Large owner Adar1 Capital Management, Llc bought $5 worth of shares (4 units at $1.32) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-adar1-capital-management-llc-bought-5-worth-of-6759030)
- 2026-10-27 01:08 UTC [SEC Form 425] [SEC Form 425 filed by InMed Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-inmed-pharmaceuticals-inc-6758231)
- 2026-10-20 21:31 UTC [Insider Buy] [Large owner Adar1 Capital Management, Llc bought $1,435 worth of shares (1,087 units at $1.32) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-adar1-capital-management-llc-bought-1435-worth-of-6752483)
- 2026-10-15 20:39 UTC [Insider Buy] [Large owner Adar1 Capital Management, Llc bought $11,418 worth of shares (8,585 units at $1.33) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-adar1-capital-management-llc-bought-11418-worth-of-6748246)
- 2026-10-08 22:27 UTC [Insider Buy] [Large owner Adar1 Capital Management, Llc bought $4,051 worth of shares (3,046 units at $1.33) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-adar1-capital-management-llc-bought-4051-worth-of-6742160)
- 2026-10-05 21:11 UTC [Insider Buy] [Large owner Adar1 Capital Management, Llc bought $35,230 worth of shares (26,489 units at $1.33) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-adar1-capital-management-llc-bought-35230-worth-of-6737477)
- 2026-10-02 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by InMed Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-inmed-pharmaceuticals-inc-6733379)
- 2026-10-01 20:18 UTC [SEC Form 424B3] [SEC Form 424B3 filed by InMed Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-inmed-pharmaceuticals-inc-6732544)
- 2026-09-29 21:07 UTC [SEC Form S-4] [Amendment: SEC Form S-4/A filed by InMed Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-4a-filed-by-inmed-pharmaceuticals-inc-6729503)
- 2026-09-18 21:11 UTC [SEC Form 8-K] [InMed Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inmed-pharmaceuticals-inc-filed-sec-form-8-k-notice-of-delisting-6720828)
- 2026-09-16 22:58 UTC [Insider Buy] [Large owner Adar1 Capital Management, Llc bought $118,076 worth of shares (91,101 units at $1.30) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-adar1-capital-management-llc-bought-118076-worth-of-6718096)
- 2026-09-09 21:11 UTC [SEC Form S-4] [Amendment: SEC Form S-4/A filed by InMed Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-4a-filed-by-inmed-pharmaceuticals-inc-6710358)
- 2026-09-09 20:54 UTC [SEC Form 425] [SEC Form 425 filed by InMed Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-inmed-pharmaceuticals-inc-6710274)
- 2026-09-09 20:31 UTC [SEC Form 10-K] [SEC Form 10-K filed by InMed Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-inmed-pharmaceuticals-inc-6710198)
- 2026-07-22 20:31 UTC [SEC Form 425] [SEC Form 425 filed by InMed Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-inmed-pharmaceuticals-inc-6645523)
- 2026-07-22 20:30 UTC [SEC Form 425] [SEC Form 425 filed by InMed Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-inmed-pharmaceuticals-inc-6645497)
- 2026-07-22 20:28 UTC [SEC Form 8-K] [InMed Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inmed-pharmaceuticals-inc-filed-sec-form-8-k-other-events-regulation-6645458)
- 2026-07-22 11:00 UTC [Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline](https://www.quantisnow.com/insight/mentari-therapeutics-announces-200-million-private-placement-for-migraine-prevention-6644538)
- 2026-07-20 20:26 UTC [SEC Form 425] [SEC Form 425 filed by InMed Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-inmed-pharmaceuticals-inc-6642563)
- 2026-07-17 23:29 UTC [Insider Buy] [Large owner Adar1 Capital Management, Llc bought $1,555 worth of shares (1,000 units at $1.55) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-adar1-capital-management-llc-bought-1555-worth-of-6641595)
- 2026-07-17 01:58 UTC [Insider Buy] [Large owner Vivo Opportunity, Llc bought $31,846 worth of shares (20,546 units at $1.55) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-vivo-opportunity-llc-bought-31846-worth-of-shares-6640359)
- 2026-07-10 20:04 UTC [SEC Form 425] [SEC Form 425 filed by InMed Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-inmed-pharmaceuticals-inc-6634045)
- 2026-07-10 20:02 UTC [SEC Form 8-K] [InMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/inmed-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-6634031)
- 2026-07-02 23:02 UTC [Insider Buy] [Large owner Vivo Opportunity, Llc bought $10,148 worth of shares (6,551 units at $1.55) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-vivo-opportunity-llc-bought-10148-worth-of-shares-6626807)
- 2026-07-02 20:03 UTC [SEC Form S-4] [SEC Form S-4 filed by InMed Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-4-filed-by-inmed-pharmaceuticals-inc-6625043)
- 2026-06-11 01:14 UTC [Insider Buy] [Large owner Vivo Opportunity, Llc bought $391,555 worth of shares (249,227 units at $1.57) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-vivo-opportunity-llc-bought-391555-worth-of-shares-6597924)
- 2026-06-11 01:14 UTC [SEC Form 3] [New insider Vivo Opportunity, Llc claimed ownership of 541,752 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-vivo-opportunity-llc-claimed-ownership-of-541752-shares-6597923)
- 2026-06-10 10:01 UTC [SEC Form 8-K] [InMed Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/inmed-pharmaceuticals-inc-filed-sec-form-8-k-other-events-financial-6596240)
- 2026-06-04 21:00 UTC [InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements](https://www.quantisnow.com/insight/inmed-pharmaceuticals-regains-compliance-with-nasdaq-continued-listing-requirements-6589885)
- 2026-05-21 21:08 UTC [Insider Buy] [Large owner Adar1 Capital Management, Llc bought $721,548 worth of shares (468,551 units at $1.54) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-adar1-capital-management-llc-bought-721548-worth-of-6568132)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/INM
- Earnings history: https://www.quantisnow.com/earnings/INM
- Dividend history: https://www.quantisnow.com/dividends/INM
- Insider transactions: https://www.quantisnow.com/insiders/INM
- Options chain: https://www.quantisnow.com/options/INM
- SEC 8-K filings only: https://www.quantisnow.com/company/INM/8-k
- RSS and alerts for INM: https://www.quantisnow.com/docs/rss-feeds.md
